Modulation of natural killer cell-mediated cytotoxicity by partially purified and cloned interferon-α

E. Lotzova, C. A. Savary, J. U. Gutterman, Evan M Hersh

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

We have studied peripheral blood of 35 normal individuals, 28 solid-cancer patients, and 14 leukemic patients for natural killer (NK) cell cytotoxicity to K-562 and CEM tumor cells in a 51Cr release cytotoxicity assay. We have found that both normal individuals and solid-cancer patients could be grouped into high (NK-HR), medium (NK-MR), and low (NK-LR) NK cell responder categories with regard to their degree of NK cell activities. However, in general, NK-HRs were found to be prevalent in normal donor population and Nk-LRs in cancer patients. Leukemic patients always exhibited the NK-LR status. The difference between NK-HRs and NK-MRs appeared to be due to the relative decrease in number of active NK cells. In contrast, the NK-LR status could not be contributed to decrease of NK cells because of the dichotomy in NK cell dose-response patterns of NK-LRs versus those of NK-HRs and NK-MRs. Eighteen cancer patients undergoing interferon-α (IFN-α) therapy (3 X 106 units, i.m., daily) were also tested for NK cell activities after single or multiple IFN-α injections. There was a highly significant and consistent increase in NK cell cytotoxicity of patients with the NK-LR and NK-MR phenotypes following one injection of IFN-α. In contrast to the NK-LR and NK-MR group of patients, most patients displaying the NK-HR phenotype failed to show any NK cell augmentation following any number of IFN-α injections (up to 119). We have also tested NK cell activities of cancer patients undergoing treatment with low (3 X 106 units) and high (36 X 106 and 50 X 106 units) doses of clone A of recombinant IFN-α (IFN-αrA). In these studies, all patients receiving the lower dose of IFN-αrA and three of five patients receiving the higher doses of IFN-αrA displayed augmented NK cell activity 24 hr after a single i.m. injection. Analysis of patients receiving the low dose of IF-αrA in a single-cell assay suggested that this agent did not modulate tumor-NK cell-binding properties but augmented significantly NK cell cytotoxicity and killing of already-bound tumor targets.

Original languageEnglish (US)
Pages (from-to)2480-2488
Number of pages9
JournalCancer Research
Volume42
Issue number6
StatePublished - 1982
Externally publishedYes

Fingerprint

Natural Killer Cells
Interferons
Neoplasms
Injections
Phenotype
Clone Cells
Tissue Donors

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Modulation of natural killer cell-mediated cytotoxicity by partially purified and cloned interferon-α. / Lotzova, E.; Savary, C. A.; Gutterman, J. U.; Hersh, Evan M.

In: Cancer Research, Vol. 42, No. 6, 1982, p. 2480-2488.

Research output: Contribution to journalArticle

Lotzova, E. ; Savary, C. A. ; Gutterman, J. U. ; Hersh, Evan M. / Modulation of natural killer cell-mediated cytotoxicity by partially purified and cloned interferon-α. In: Cancer Research. 1982 ; Vol. 42, No. 6. pp. 2480-2488.
@article{4aa5335913604f3e8fc750ca38a0690f,
title = "Modulation of natural killer cell-mediated cytotoxicity by partially purified and cloned interferon-α",
abstract = "We have studied peripheral blood of 35 normal individuals, 28 solid-cancer patients, and 14 leukemic patients for natural killer (NK) cell cytotoxicity to K-562 and CEM tumor cells in a 51Cr release cytotoxicity assay. We have found that both normal individuals and solid-cancer patients could be grouped into high (NK-HR), medium (NK-MR), and low (NK-LR) NK cell responder categories with regard to their degree of NK cell activities. However, in general, NK-HRs were found to be prevalent in normal donor population and Nk-LRs in cancer patients. Leukemic patients always exhibited the NK-LR status. The difference between NK-HRs and NK-MRs appeared to be due to the relative decrease in number of active NK cells. In contrast, the NK-LR status could not be contributed to decrease of NK cells because of the dichotomy in NK cell dose-response patterns of NK-LRs versus those of NK-HRs and NK-MRs. Eighteen cancer patients undergoing interferon-α (IFN-α) therapy (3 X 106 units, i.m., daily) were also tested for NK cell activities after single or multiple IFN-α injections. There was a highly significant and consistent increase in NK cell cytotoxicity of patients with the NK-LR and NK-MR phenotypes following one injection of IFN-α. In contrast to the NK-LR and NK-MR group of patients, most patients displaying the NK-HR phenotype failed to show any NK cell augmentation following any number of IFN-α injections (up to 119). We have also tested NK cell activities of cancer patients undergoing treatment with low (3 X 106 units) and high (36 X 106 and 50 X 106 units) doses of clone A of recombinant IFN-α (IFN-αrA). In these studies, all patients receiving the lower dose of IFN-αrA and three of five patients receiving the higher doses of IFN-αrA displayed augmented NK cell activity 24 hr after a single i.m. injection. Analysis of patients receiving the low dose of IF-αrA in a single-cell assay suggested that this agent did not modulate tumor-NK cell-binding properties but augmented significantly NK cell cytotoxicity and killing of already-bound tumor targets.",
author = "E. Lotzova and Savary, {C. A.} and Gutterman, {J. U.} and Hersh, {Evan M}",
year = "1982",
language = "English (US)",
volume = "42",
pages = "2480--2488",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - Modulation of natural killer cell-mediated cytotoxicity by partially purified and cloned interferon-α

AU - Lotzova, E.

AU - Savary, C. A.

AU - Gutterman, J. U.

AU - Hersh, Evan M

PY - 1982

Y1 - 1982

N2 - We have studied peripheral blood of 35 normal individuals, 28 solid-cancer patients, and 14 leukemic patients for natural killer (NK) cell cytotoxicity to K-562 and CEM tumor cells in a 51Cr release cytotoxicity assay. We have found that both normal individuals and solid-cancer patients could be grouped into high (NK-HR), medium (NK-MR), and low (NK-LR) NK cell responder categories with regard to their degree of NK cell activities. However, in general, NK-HRs were found to be prevalent in normal donor population and Nk-LRs in cancer patients. Leukemic patients always exhibited the NK-LR status. The difference between NK-HRs and NK-MRs appeared to be due to the relative decrease in number of active NK cells. In contrast, the NK-LR status could not be contributed to decrease of NK cells because of the dichotomy in NK cell dose-response patterns of NK-LRs versus those of NK-HRs and NK-MRs. Eighteen cancer patients undergoing interferon-α (IFN-α) therapy (3 X 106 units, i.m., daily) were also tested for NK cell activities after single or multiple IFN-α injections. There was a highly significant and consistent increase in NK cell cytotoxicity of patients with the NK-LR and NK-MR phenotypes following one injection of IFN-α. In contrast to the NK-LR and NK-MR group of patients, most patients displaying the NK-HR phenotype failed to show any NK cell augmentation following any number of IFN-α injections (up to 119). We have also tested NK cell activities of cancer patients undergoing treatment with low (3 X 106 units) and high (36 X 106 and 50 X 106 units) doses of clone A of recombinant IFN-α (IFN-αrA). In these studies, all patients receiving the lower dose of IFN-αrA and three of five patients receiving the higher doses of IFN-αrA displayed augmented NK cell activity 24 hr after a single i.m. injection. Analysis of patients receiving the low dose of IF-αrA in a single-cell assay suggested that this agent did not modulate tumor-NK cell-binding properties but augmented significantly NK cell cytotoxicity and killing of already-bound tumor targets.

AB - We have studied peripheral blood of 35 normal individuals, 28 solid-cancer patients, and 14 leukemic patients for natural killer (NK) cell cytotoxicity to K-562 and CEM tumor cells in a 51Cr release cytotoxicity assay. We have found that both normal individuals and solid-cancer patients could be grouped into high (NK-HR), medium (NK-MR), and low (NK-LR) NK cell responder categories with regard to their degree of NK cell activities. However, in general, NK-HRs were found to be prevalent in normal donor population and Nk-LRs in cancer patients. Leukemic patients always exhibited the NK-LR status. The difference between NK-HRs and NK-MRs appeared to be due to the relative decrease in number of active NK cells. In contrast, the NK-LR status could not be contributed to decrease of NK cells because of the dichotomy in NK cell dose-response patterns of NK-LRs versus those of NK-HRs and NK-MRs. Eighteen cancer patients undergoing interferon-α (IFN-α) therapy (3 X 106 units, i.m., daily) were also tested for NK cell activities after single or multiple IFN-α injections. There was a highly significant and consistent increase in NK cell cytotoxicity of patients with the NK-LR and NK-MR phenotypes following one injection of IFN-α. In contrast to the NK-LR and NK-MR group of patients, most patients displaying the NK-HR phenotype failed to show any NK cell augmentation following any number of IFN-α injections (up to 119). We have also tested NK cell activities of cancer patients undergoing treatment with low (3 X 106 units) and high (36 X 106 and 50 X 106 units) doses of clone A of recombinant IFN-α (IFN-αrA). In these studies, all patients receiving the lower dose of IFN-αrA and three of five patients receiving the higher doses of IFN-αrA displayed augmented NK cell activity 24 hr after a single i.m. injection. Analysis of patients receiving the low dose of IF-αrA in a single-cell assay suggested that this agent did not modulate tumor-NK cell-binding properties but augmented significantly NK cell cytotoxicity and killing of already-bound tumor targets.

UR - http://www.scopus.com/inward/record.url?scp=0020030925&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020030925&partnerID=8YFLogxK

M3 - Article

C2 - 6176319

AN - SCOPUS:0020030925

VL - 42

SP - 2480

EP - 2488

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 6

ER -